About

Heart failure (HF) is a rapidly growing public health issue with an estimated prevalence of >37.7 million individuals globally. HF is a shared chronic phase of cardiac functional impairment secondary to many aetiologies, and patients with HF experience a range of symptoms that affect their quality of life, including dyspnoea, fatigue, poor exercise tolerance and fluid retention.

The burden of HF will continue to rise, due to population aging, population growth and improved treatment of HF and other cardiovascular disorders. As a result, clinicians will be increasingly challenged to develop treatment plans and care systems that reduce the high levels of morbidity and mortality experienced by these patients, both from their HF and other comorbidities.

Visit our Heart Failure Management Hub to discover a range of educational content to facilitate the use of SGLT-2 inhibitors and other guideline directed medical therapies as foundational treatment for HF.

Articles

A31 - Institutional Experience with Impella 5.0 and its Effect on Renal Function

Published:

11 November 2019

Citation:

Interventional Cardiology Review 2019;14(3 Suppl 1):A31.

A25 - A Novel Superior Vena Caval Occlusion Catheter System Reduces Biventricular Filling Pressures While Maintaining Cardiac Output in a Model of Acute Congestive Heart Failure

Published:

11 November 2019

Citation:

Interventional Cardiology Review 2019;14(3 Suppl 1):A25.

A16 - Yamanaka Factors as Drivers of Recovery in a Mouse Model of Heart Failure

Published:

11 November 2019

Citation:

Interventional Cardiology Review 2019;14(3 Suppl 1):A16.

A14 - Haemodynamic and Metabolic Changes Due to Left Ventricular Unloading by Impella Heart Pump in Patients Suffering from Cardiogenic Shock Within 24 Hours: Results from the Jenamacs Impella Registry

Published:

11 November 2019

Citation:

Interventional Cardiology Review 2019;14(3 Suppl 1):A14.